These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 11246876

  • 1. Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes.
    Vella A, Shah P, Basu R, Basu A, Camilleri M, Schwenk FW, Holst JJ, Rizza RA.
    Diabetes; 2001 Mar; 50(3):565-72. PubMed ID: 11246876
    [Abstract] [Full Text] [Related]

  • 2. Type I diabetes mellitus does not alter initial splanchnic glucose extraction or hepatic UDP-glucose flux during enteral glucose administration.
    Vella A, Shah P, Basu R, Basu A, Camilleri M, Schwenk WF, Rizza RA.
    Diabetologia; 2001 Jun; 44(6):729-37. PubMed ID: 11440366
    [Abstract] [Full Text] [Related]

  • 3. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.
    Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA.
    Diabetes; 2000 Apr; 49(4):611-7. PubMed ID: 10871199
    [Abstract] [Full Text] [Related]

  • 4. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
    Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA.
    Diabetologia; 2002 Oct; 45(10):1410-5. PubMed ID: 12378382
    [Abstract] [Full Text] [Related]

  • 5. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
    Sandhu H, Wiesenthal SR, MacDonald PE, McCall RH, Tchipashvili V, Rashid S, Satkunarajah M, Irwin DM, Shi ZQ, Brubaker PL, Wheeler MB, Vranic M, Efendic S, Giacca A.
    Diabetes; 1999 May; 48(5):1045-53. PubMed ID: 10331409
    [Abstract] [Full Text] [Related]

  • 6. Effects of free fatty acids and glycerol on splanchnic glucose metabolism and insulin extraction in nondiabetic humans.
    Shah P, Vella A, Basu A, Basu R, Adkins A, Schwenk WF, Johnson CM, Nair KS, Jensen MD, Rizza RA.
    Diabetes; 2002 Feb; 51(2):301-10. PubMed ID: 11812736
    [Abstract] [Full Text] [Related]

  • 7. Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity.
    Basu A, Basu R, Shah P, Vella A, Johnson CM, Nair KS, Jensen MD, Schwenk WF, Rizza RA.
    Diabetes; 2000 Feb; 49(2):272-83. PubMed ID: 10868944
    [Abstract] [Full Text] [Related]

  • 8. GLP-1 does not not acutely affect insulin sensitivity in healthy man.
    Orskov L, Holst JJ, Møller J, Orskov C, Møller N, Alberti KG, Schmitz O.
    Diabetologia; 1996 Oct; 39(10):1227-32. PubMed ID: 8897012
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA.
    Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
    [Abstract] [Full Text] [Related]

  • 12. Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes.
    Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Elahi D.
    J Gerontol A Biol Sci Med Sci; 2001 Nov; 56(11):M681-5. PubMed ID: 11682575
    [Abstract] [Full Text] [Related]

  • 13. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.
    Egan JM, Meneilly GS, Habener JF, Elahi D.
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3768-73. PubMed ID: 12161508
    [Abstract] [Full Text] [Related]

  • 14. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    Toft-Nielsen MB, Madsbad S, Holst JJ.
    Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
    [Abstract] [Full Text] [Related]

  • 15. Effects of hepatic glycogen content on hepatic insulin action in humans: alteration in the relative contributions of glycogenolysis and gluconeogenesis to endogenous glucose production.
    Wise S, Nielsen M, Rizza R.
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1828-33. PubMed ID: 9177391
    [Abstract] [Full Text] [Related]

  • 16. Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes.
    Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Ehlers MR, Egan JM, Elahi D.
    Diabetes Care; 2003 Mar; 26(3):837-42. PubMed ID: 12610046
    [Abstract] [Full Text] [Related]

  • 17. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC.
    Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
    [Abstract] [Full Text] [Related]

  • 18. Effect of enteral vs. parenteral glucose delivery on initial splanchnic glucose uptake in nondiabetic humans.
    Vella A, Shah P, Basu R, Basu A, Camilleri M, Schwenk WF, Rizza RA.
    Am J Physiol Endocrinol Metab; 2002 Aug; 283(2):E259-66. PubMed ID: 12110530
    [Abstract] [Full Text] [Related]

  • 19. Assessment of hepatic sensitivity to glucagon in NIDDM: use as a tool to estimate the contribution of the indirect pathway to nocturnal glycogen synthesis.
    Nielsen MF, Wise S, Dinneen SF, Schwenk WF, Basu A, Rizza RA.
    Diabetes; 1997 Dec; 46(12):2007-16. PubMed ID: 9392488
    [Abstract] [Full Text] [Related]

  • 20. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.
    Byrne MM, Gliem K, Wank U, Arnold R, Katschinski M, Polonsky KS, Göke B.
    Diabetes; 1998 Aug; 47(8):1259-65. PubMed ID: 9703326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.